Biodesix to buy U.S. lab, lung nodule test from Oncimmune
The deal, which would become effective Nov. 1, is valued at up to $28 million over the next five years. Biodesix will acquire the UK company's US lab in Kansas.
Biodesix acquires Seattle-based developer of blood-based lung nodule test
Acquisition of Integrated Diagnostics gives Biodesix control of test to determine if nodules are benign or malignant.
Transforming Clinical Content with Ambient & Generative AI
Sheila Bond, MD, talked about the latest trends regarding integration of AI in healthcare.